Opko Health, Inc. (NASDAQ:OPK) Receives Hold Rating from Jefferies Group LLC
Jefferies Group LLC reissued their hold rating on shares of Opko Health, Inc. (NASDAQ:OPK) in a research report released on Thursday. They currently have a $8.00 price target on the biotechnology company’s stock.
Several other research firms have also recently issued reports on OPK. Zacks Investment Research cut shares of Opko Health from a hold rating to a sell rating in a report on Thursday, May 4th. Ladenburg Thalmann Financial Services reiterated a buy rating and issued a $19.50 price objective on shares of Opko Health in a report on Friday, June 16th. BidaskClub upgraded shares of Opko Health from a strong sell rating to a sell rating in a report on Thursday, June 22nd. Finally, Barrington Research increased their price objective on shares of Opko Health to $11.00 and gave the company an outperform rating in a report on Tuesday, July 18th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $14.72.
Shares of Opko Health (NASDAQ:OPK) traded up 1.43% during midday trading on Thursday, reaching $6.40. The company’s stock had a trading volume of 2,334,806 shares. The stock has a 50 day moving average of $6.48 and a 200-day moving average of $7.46. Opko Health has a 1-year low of $5.99 and a 1-year high of $12.15. The company’s market capitalization is $3.58 billion.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.02. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The firm had revenue of $296.10 million during the quarter, compared to analyst estimates of $313.36 million. During the same quarter in the previous year, the business posted ($0.02) EPS. Opko Health’s revenue for the quarter was up 1.8% compared to the same quarter last year. On average, equities research analysts anticipate that Opko Health will post ($0.20) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Opko Health, Inc. (NASDAQ:OPK) Receives Hold Rating from Jefferies Group LLC” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/opko-health-inc-nasdaqopk-receives-hold-rating-from-jefferies-group-llc/1464200.html.
In other news, Vice Chairman Jane Ph D. Hsiao acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The stock was purchased at an average price of $6.93 per share, with a total value of $138,600.00. Following the purchase, the insider now owns 24,763,133 shares of the company’s stock, valued at approximately $171,608,511.69. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Phillip Md Et Al Frost acquired 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was purchased at an average cost of $7.58 per share, with a total value of $113,700.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $23,262,648.58. The disclosure for this purchase can be found here. Insiders have purchased 2,832,200 shares of company stock valued at $18,905,965 over the last 90 days. 40.19% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the company. Financial Architects Inc raised its position in Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock worth $102,000 after buying an additional 4,800 shares in the last quarter. AQR Capital Management LLC purchased a new position in Opko Health during the fourth quarter worth approximately $105,000. Timber Hill LLC purchased a new position in Opko Health during the first quarter worth approximately $114,000. Comerica Bank purchased a new position in Opko Health during the fourth quarter worth approximately $117,000. Finally, World Asset Management Inc raised its position in Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,900 shares in the last quarter. 23.65% of the stock is owned by hedge funds and other institutional investors.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.